You are here

Article Text

Article menu

Download PDFPDF

Endometrial cancer
2022-RA-449-ESGO Clinical-molecular correlations of endometrial cancer. Retrospective study
Free
  1. Natalia Pérez Rodríguez1,
  2. Alfonso Quesada López2,
  3. María López Acosta3,
  4. Jose Antonio Pérez Álvarez2,
  5. Mónica Vilar Chesa4,
  6. Vanesa Concepción Martín5,
  7. Jose Javier Martin Ortega6 and
  8. Pablo Martín Vasallo7
  1. 1Medical Oncology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
  2. 2Gynecology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
  3. 3Nuclear Medicine, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
  4. 4Pathological Anatomy, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
  5. 5Surgery, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
  6. 6Oncology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
  7. 7Biochemistry and Molecular Biology, University de la Laguna, Santa Cruz de Tenerife, Spain

Abstract

Introduction/Background Endometrial cancer (EC) is the most common gynecological tumor in developed countries, with more than 75% diagnosed at early stages. It is associated in 20–30% with microsatellite instability (MSI) due to mutations in the MMR genes, which can be sporadic (80–90%) or hereditary (10–20%) such as Lynch syndrome (LS).Objective: To establish the clinical-molecular profile of endometrial carcinoma and its implication for treatment.

Methodology Retrospective cross-sectional observational study. 162 patients diagnosed with EC during the period 2010–2020 and treated in Medical Oncology Service at the HUNSC were studied.Study variables: age, histology grade and type, stage, hormone receptors (HR), MSI, LS, overall survival. SPSS 25 was used for statistical analysis.

Abstract 2022-RA-449-ESGO Figure 1
Abstract 2022-RA-449-ESGO Figure 1

Results The median age was 64,51 years. The most frequent stages at diagnosis were IA (25.3%) and IB (24.7%). Histologically, endometrioid adenocarcinoma accounted for 51.2% and grade 3 for 41.4% of cases. Patients with LS were mainly diagnosed at stage III, being endometrioid or serous adenocarcinomas, and mainly grade 3 (60%). Overall survival was longer in the HR+ group (40.5 months). MSI-H was observed in 36.1% of the sample and the dMMR distribution: MLH1 (27.9%) and PMS2 (24.6%), MSH2 (16.4%), MSH6 (13.1%). Ten patients were diagnosed with LS.

Abstract 2022-RA-449-ESGO Figure 2
Abstract 2022-RA-449-ESGO Figure 2

Conclusion Our EC and LS results are comparable to those published for other settings. There is a significant association between HR+ and longer overall survival. The percentage of dMMR/MSI-H is higher than reported in other studies. Further studies with a larger sample would be needed.

https://doi.org/10.1136/ijgc-2022-ESGO.211

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.